View Older Stories

Apr 17, 2026 03:28AM Rothschild Redburn Starts Repligen (RGEN) at Buy

Mar 23, 2026 06:44AM Repligen (RGEN) PT Raised to $208 at H.C. Wainwright

Mar 20, 2026 06:05AM Evercore: ' Latest Survey Work Positions 2026 As Better Year For Biopharma Spending'

Feb 25, 2026 08:32AM KeyBanc on Repligen (RGEN): '4Q25 Momentum Points to Conservative 2026'

Feb 24, 2026 07:36AM Repligen (RGEN) Tops Q4 EPS by 5c; offers guidance

Jan 16, 2026 09:37AM Repligen (RGEN) PT Raised to $200 at UBS on Bioprocessing Recovery

Jan 8, 2026 09:30AM Halozyme Therapeutics (HALO) PT Raised at TD Cowen; 'One of Our Top Picks for 2026'

Jan 6, 2026 07:31AM Repligen names Dr. Martin Madaus as board chair as Tony Hunt retires

Dec 16, 2025 07:30AM Repligen launches three new chromatography resins for gene therapy

Dec 8, 2025 07:11AM KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'

Nov 12, 2025 08:43AM Repligen (RGEN): No reason to change bullish stance on stock, says Stifel

Oct 28, 2025 01:41PM Repligen (RGEN) PT Raised to $160 at Jefferies

Oct 28, 2025 07:33AM Repligen (RGEN) Tops Q3 EPS by 4c ; Offers Guidance

Oct 1, 2025 03:55AM HSBC Starts Repligen (RGEN) at Buy

Sep 23, 2025 07:29AM KeyBanc Takeaways from This Year's BioProcess International Conference

Sep 23, 2025 07:26AM KeyBanc Reiterates Overweight Rating on Repligen (RGEN)

Sep 22, 2025 06:02AM Evercore ISI Upgrades Repligen (NASDAQ: RGEN) to Outperform (correction)

Sep 17, 2025 07:53AM TD Cowen Reiterates Buy Rating on Repligen (RGEN), Still a Top Pick

Sep 16, 2025 08:39AM Stifel Reiterates Buy Rating on Repligen (RGEN)

Sep 11, 2025 04:06PM Repligen (RGEN) PT Lowered to $135 at Jefferies

Sep 3, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Repligen (RGEN)

Jul 30, 2025 08:47AM KeyBanc Reiterates Overweight Rating on Repligen (RGEN)

Jul 29, 2025 07:32AM Repligen (RGEN) Misses Q2 EPS by 2c; offers guidance

Jun 24, 2025 06:18AM Barclays Starts Repligen (RGEN) at Overweight

Jun 16, 2025 08:02AM 908 Devices (MASS) Appoints Christopher D. Brown to its Board of Directors

Jun 9, 2025 03:28PM Maravai LifeSciences (MRVI) on watch on vague chatter following CEO change

May 30, 2025 12:34PM Repligen (RGEN) Trading LOD, Down 3.6pct

Apr 29, 2025 04:03PM Repligen (RGEN) PT Lowered to $940 at Truist Securities

Apr 29, 2025 03:58PM Repligen (RGEN) PT Lowered to $914 at Jefferies

Apr 29, 2025 02:54PM Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'

Apr 29, 2025 07:33AM Repligen (RGEN) Tops Q1 EPS by 4c, provides guidance

Mar 17, 2025 04:05PM Evercore ISI Starts Repligen (RGEN) at In Line

Mar 4, 2025 09:50AM Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)

Mar 4, 2025 07:32AM Repligen (RGEN) Purchases Bioprocessing Analytics Portfolio from 908 Devices (MASS)

Feb 28, 2025 10:02AM TD Cowen Issues Stock Conclusions Following Bioproduction Market Survey

Feb 24, 2025 08:42AM Benchmark Reiterates Hold Rating on Repligen (RGEN)

Feb 21, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Repligen (RGEN)

Feb 21, 2025 06:37AM Repligen (RGEN) PT Raised to $170 at Canaccord Genuity

Feb 21, 2025 04:35AM KeyBanc Reiterates Overweight Rating on Repligen (RGEN)

Feb 20, 2025 01:57PM Repligen (RGEN) PT Raised to $165 at Jefferies

Feb 20, 2025 07:38AM Repligen (RGEN) Tops Q4 EPS by 3c ; Offers Guidance

Feb 10, 2025 05:30AM TD Cowen Starts Repligen (RGEN) at Buy

Jan 6, 2025 07:30AM Repligen (RGEN) Launches the CTech SoloVPE PLUS System

Dec 16, 2024 04:12PM Canaccord Genuity Starts Repligen (RGEN) at Hold

Dec 9, 2024 07:36AM Repligen (RGEN) Launches Novel AVIPure dsRNA Resin in OPUS® Pre-packed Columns

Nov 14, 2024 06:04AM Wolfe Research Starts Repligen (RGEN) at Peerperform

Nov 12, 2024 02:45PM KeyBanc Reiterates Overweight Rating on Repligen (RGEN)

Nov 12, 2024 07:35AM Repligen (RGEN) Tops Q3 EPS by 10c ; Offers Guidance

Sep 18, 2024 04:38PM After-hours movers: Steelcase, Hess Midstream Partners, Repligen

Sep 18, 2024 04:25PM Repligen (RGEN) Reports Non-Reliance on Previously Issued Financial Statements

View Older Stories